Metraipolis › archive › dc_2f17ea5b6474
Venetoclax-Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview — Europe PMC PMID:41097687
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41097687
- DOI
- 10.3390/cancers17193159
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T17:33:24.568Z
- SHA-256 of the archived text
a7c07b0c5c5a14f04f2de704416afe7d3643322a58f061f13b2994de9d99d746- Stable URL of this page
https://metraipolis.com/documento/dc_2f17ea5b6474
How to cite
Venetoclax-Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview — Europe PMC PMID:41097687 — Europe PMC (en), https://europepmc.org/article/MED/41097687 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2f17ea5b6474 (Metraipolis archive dc_2f17ea5b6474, sha256 a7c07b0c5c5a14f04f2de704416afe7d3643322a58f061f13b2994de9d99d746)
BibTeX
@misc{dc2f17ea5b6474,
title = {Venetoclax-Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview — Europe PMC PMID:41097687},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41097687},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2f17ea5b6474; sha256 a7c07b0c5c5a14f04f2de704416afe7d3643322a58f061f13b2994de9d99d746},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41097687. Agents can read the archived copy with the MCP tool read_document.